@prefix	rdfs:	<http://www.w3.org/2000/01/rdf-schema#>	.
@prefix	local:	<http://local/local.owl#>	.
@prefix	ncit:	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#>	.
@prefix	rdf:	<http://www.w3.org/1999/02/22-rdf-syntax-ns#>	.
@prefix	owl:	<http://www.w3.org/2002/07/owl#>	.

#### Statements ####

local:s29.1	a	rdf:Statement	;
	rdfs:label	"early use improve outcomes"	.

local:s29	a	rdf:Statement	;
	rdfs:label	"early use appears to improve outcomes"	.

local:s27.2	a	rdf:Statement	;
	rdfs:label	"cortisone sparing in antibodypositive"	.

local:s27.1	a	rdf:Statement	;
	rdfs:label	"early use facilitate cortisone sparing in antibodypositive"	.

local:s27	a	rdf:Statement	;
	rdfs:label	"early use appears to facilitate cortisone sparing in antibodypositive"	.

local:s26	a	rdf:Statement	;
	rdfs:label	"this study suggests good tolerability and efficacy of rituximab in juvenile myasthenia gravis"	.

local:s25	a	rdf:Statement	;
	rdfs:label	"the use of rituximab as a firstline immunosuppressant increased in france over the last 10 years as a firstline immunosuppressant"	.

local:s24	a	rdf:Statement	;
	rdfs:label	"rituximab well tolerated"	.

local:s23.1	a	rdf:Statement	;
	rdfs:label	"cortisone sparing compared with rituximab treatment as thirdline immunosuppression"	.

local:s23	a	rdf:Statement	;
	rdfs:label	"the use of rituximab as a firstline immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75 percent of results in cortisone sparing compared with rituximab treatment as thirdline immunosuppression"	.

local:s22.1	a	rdf:Statement	;
	rdfs:label	"cortisone sparing compared with rituximab treatment as a secondline"	.

local:s22	a	rdf:Statement	;
	rdfs:label	"the use of rituximab as a firstline immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75 percent of patients in cortisone sparing compared with rituximab treatment as a secondline"	.

local:s21.1	a	rdf:Statement	;
	rdfs:label	"cortisone sparing compared with rituximab treatment as thirdline immunosuppression"	.

local:s21	a	rdf:Statement	;
	rdfs:label	"the use of rituximab as a firstline immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75 percent of patients in cortisone sparing compared with rituximab treatment as thirdline immunosuppression"	.

local:s20.1	a	rdf:Statement	;
	rdfs:label	"cortisone sparing compared with rituximab treatment as a secondline"	.

local:s20	a	rdf:Statement	;
	rdfs:label	"the use of rituximab as a firstline immunosuppressant showed a better efficacy with a discontinuation of immunosuppressants in 75 percent of results in cortisone sparing compared with rituximab treatment as a secondline"	.

local:s19	a	rdf:Statement	;
	rdfs:label	"patients treated with rituximab"	.

local:s18	a	rdf:Statement	;
	rdfs:label	"patients had a better outcome than patients"	.

local:s17	a	rdf:Statement	;
	rdfs:label	"patients treated with conventional immunosuppressants"	.

local:s16	a	rdf:Statement	;
	rdfs:label	"outcome defined as the therapeutic status of patients at the last visit"	.

local:s15	a	rdf:Statement	;
	rdfs:label	"outcome defined stable without immunosuppressants stable with immunosuppressants"	.

local:s14	a	rdf:Statement	;
	rdfs:label	"outcome defined as the clinical status of patients at the last visit"	.

local:s12.1	a	rdf:Statement	;
	rdfs:label	"to evaluate the efficacy of rituximab we studied the clinical course of patients on immunosuppressive therapy"	.

local:s12	a	rdf:Statement	;
	rdfs:label	"evaluate the efficacy of rituximab we"	.

local:s11	a	rdf:Statement	;
	rdfs:label	"different lines of immunosuppressive treatment"	.

local:s10	a	rdf:Statement	;
	rdfs:label	"clinical course of the patients"	.

local:s9	a	rdf:Statement	;
	rdfs:label	"the type of myasthenia"	.

local:s8.1	a	rdf:Statement	;
	rdfs:label	"a retrospective multicenter study april 30 2020"	.

local:s8	a	rdf:Statement	;
	rdfs:label	"we conducted a retrospective multicenter study from january 1 2009 to april 30 2020"	.

local:s5	a	rdf:Statement	;
	rdfs:label	"we conducted a retrospective multicenter study from january 1 2009 to"	.

local:s4.1	a	rdf:Statement	;
	rdfs:label	"propose a new place in the therapeutic strategy of juvenile myasthenia gravis"	.

local:s4	a	rdf:Statement	;
	rdfs:label	"describe the use of rituximab to propose a new place in the therapeutic strategy of juvenile myasthenia gravis"	.

local:s3.1	a	rdf:Statement	;
	rdfs:label	"the french neuromuscular reference network propose a new place in the therapeutic strategy of juvenile myasthenia gravis"	.

local:s3	a	rdf:Statement	;
	rdfs:label	"describe this study efficacy and safety in 8 main pediatric centers of the french neuromuscular reference network to propose a new place in the therapeutic strategy of juvenile myasthenia gravis"	.

local:s2	a	rdf:Statement	;
	rdfs:label	"the place of new immunosuppressive therapies not clearly defined by the last international consensus"	.

local:s1	a	rdf:Statement	;
	rdfs:label	"the last international consensus held in march 2019 due to the lack of clinical trials"	.


#### Classes ####

local:early_use	a	rdf:Class	;
	rdfs:label	"early use"	.

local:use	a	rdf:Class	;
	rdfs:label	"use"	.

local:early	a	rdf:Class	;
	rdfs:label	"early"	.

local:improve	a	rdf:Class	;
	rdfs:label	"improve"	.

local:outcome	a	rdf:Class	;
	rdfs:label	"outcome"	.

local:appear	a	rdf:Class	;
	rdfs:label	"appear"	.

local:cortisone	a	rdf:Class	;
	rdfs:label	"cortisone"	.

local:spar	a	rdf:Class	;
	rdfs:label	"spar"	.

local:antibodypositive	a	rdf:Class	;
	rdfs:label	"antibodypositive"	.

local:facilitate	a	rdf:Class	;
	rdfs:label	"facilitate"	.

local:cortisone_spar_in_antibodypositive	a	rdf:Class	;
	rdfs:label	"cortisone spar in antibodypositive"	.

local:cortisone_spar	a	rdf:Class	;
	rdfs:label	"cortisone spar"	.

local:study	a	rdf:Class	;
	rdfs:label	"study"	.

local:suggest	a	rdf:Class	;
	rdfs:label	"suggest"	.

local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	a	rdf:Class	;
	rdfs:label	"good tolerability and efficacy of rituximab in juvenile myasthenia gravis"	.

local:juvenile_myasthenia_gravis	a	rdf:Class	;
	rdfs:label	"juvenile myasthenia gravis"	.

local:rituximab	a	rdf:Class	;
	rdfs:label	"rituximab"	.

local:efficacy	a	rdf:Class	;
	rdfs:label	"efficacy"	.

local:good_tolerability	a	rdf:Class	;
	rdfs:label	"good tolerability"	.

local:myasthenia_gravis	a	rdf:Class	;
	rdfs:label	"myasthenia gravis"	.

local:myasthenia	a	rdf:Class	;
	rdfs:label	"myasthenia"	.

local:juvenile_myasthenia	a	rdf:Class	;
	rdfs:label	"juvenile myasthenia"	.

local:tolerability	a	rdf:Class	;
	rdfs:label	"tolerability"	.

local:gravis	a	rdf:Class	;
	rdfs:label	"gravis"	.

local:juvenile	a	rdf:Class	;
	rdfs:label	"juvenile"	.

local:good	a	rdf:Class	;
	rdfs:label	"good"	.

local:good_tolerability_of_rituximab	a	rdf:Class	;
	rdfs:label	"good tolerability of rituximab"	.

local:good_tolerability_of_rituximab_in_juvenile_myasthenia	a	rdf:Class	;
	rdfs:label	"good tolerability of rituximab in juvenile myasthenia"	.

local:use_of_rituximab_a_a_firstline_immunosuppressant	a	rdf:Class	;
	rdfs:label	"use of rituximab a a firstline immunosuppressant"	.

local:firstline_immunosuppressant	a	rdf:Class	;
	rdfs:label	"firstline immunosuppressant"	.

local:immunosuppressant	a	rdf:Class	;
	rdfs:label	"immunosuppressant"	.

local:firstline	a	rdf:Class	;
	rdfs:label	"firstline"	.

local:use_of_rituximab	a	rdf:Class	;
	rdfs:label	"use of rituximab"	.

local:increase	a	rdf:Class	;
	rdfs:label	"increase"	.

local:france	a	rdf:Class	;
	rdfs:label	"france"	.

local:last_10_year_a_a_firstline_immunosuppressant	a	rdf:Class	;
	rdfs:label	"last 10 year a a firstline immunosuppressant"	.

local:year	a	rdf:Class	;
	rdfs:label	"year"	.

local:10_year	a	rdf:Class	;
	rdfs:label	"10 year"	.

local:last_10_year	a	rdf:Class	;
	rdfs:label	"last 10 year"	.

local:tolerate	a	rdf:Class	;
	rdfs:label	"tolerate"	.

local:well	a	rdf:Class	;
	rdfs:label	"well"	.

local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	a	rdf:Class	;
	rdfs:label	"compare with rituximab treatment a thirdline immunosuppression"	.

local:compare	a	rdf:Class	;
	rdfs:label	"compare"	.

local:rituximab_treatment	a	rdf:Class	;
	rdfs:label	"rituximab treatment"	.

local:thirdline_immunosuppression	a	rdf:Class	;
	rdfs:label	"thirdline immunosuppression"	.

local:thirdline	a	rdf:Class	;
	rdfs:label	"thirdline"	.

local:immunosuppression	a	rdf:Class	;
	rdfs:label	"immunosuppression"	.

local:treatment	a	rdf:Class	;
	rdfs:label	"treatment"	.

local:compare_with_rituximab_treatment	a	rdf:Class	;
	rdfs:label	"compare with rituximab treatment"	.

local:show	a	rdf:Class	;
	rdfs:label	"show"	.

local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	a	rdf:Class	;
	rdfs:label	"better efficacy with a discontinuation of immunosuppressant in 75 percent of result in cortisone spar compare with rituximab treatment a thirdline immunosuppression"	.

local:percent	a	rdf:Class	;
	rdfs:label	"percent"	.

local:cortisone_spar_compare	a	rdf:Class	;
	rdfs:label	"cortisone spar compare"	.

local:better_efficacy	a	rdf:Class	;
	rdfs:label	"better efficacy"	.

local:result	a	rdf:Class	;
	rdfs:label	"result"	.

local:discontinuation	a	rdf:Class	;
	rdfs:label	"discontinuation"	.

local:spar_compare	a	rdf:Class	;
	rdfs:label	"spar compare"	.

local:better	a	rdf:Class	;
	rdfs:label	"better"	.

local:75_percent	a	rdf:Class	;
	rdfs:label	"75 percent"	.

local:better_efficacy_with_discontinuation	a	rdf:Class	;
	rdfs:label	"better efficacy with discontinuation"	.

local:discontinuation_of_immunosuppressant	a	rdf:Class	;
	rdfs:label	"discontinuation of immunosuppressant"	.

local:discontinuation_of_immunosuppressant_in_75_percent	a	rdf:Class	;
	rdfs:label	"discontinuation of immunosuppressant in 75 percent"	.

local:75_percent_of_result	a	rdf:Class	;
	rdfs:label	"75 percent of result"	.

local:result_in_cortisone_spar	a	rdf:Class	;
	rdfs:label	"result in cortisone spar"	.

local:compare_with_rituximab_treatment_a_a_secondline	a	rdf:Class	;
	rdfs:label	"compare with rituximab treatment a a secondline"	.

local:secondline	a	rdf:Class	;
	rdfs:label	"secondline"	.

local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	a	rdf:Class	;
	rdfs:label	"better efficacy with a discontinuation of immunosuppressant in 75 percent of patient in cortisone spar compare with rituximab treatment a a secondline"	.

local:patient	a	rdf:Class	;
	rdfs:label	"patient"	.

local:75_percent_of_patient	a	rdf:Class	;
	rdfs:label	"75 percent of patient"	.

local:patient_in_cortisone_spar	a	rdf:Class	;
	rdfs:label	"patient in cortisone spar"	.

local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	a	rdf:Class	;
	rdfs:label	"better efficacy with a discontinuation of immunosuppressant in 75 percent of patient in cortisone spar compare with rituximab treatment a thirdline immunosuppression"	.

local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	a	rdf:Class	;
	rdfs:label	"better efficacy with a discontinuation of immunosuppressant in 75 percent of result in cortisone spar compare with rituximab treatment a a secondline"	.

local:treat	a	rdf:Class	;
	rdfs:label	"treat"	.

local:have	a	rdf:Class	;
	rdfs:label	"have"	.

local:better_outcome_than_patient	a	rdf:Class	;
	rdfs:label	"better outcome than patient"	.

local:better_outcome	a	rdf:Class	;
	rdfs:label	"better outcome"	.

local:conventional_immunosuppressant	a	rdf:Class	;
	rdfs:label	"conventional immunosuppressant"	.

local:conventional	a	rdf:Class	;
	rdfs:label	"conventional"	.

local:define	a	rdf:Class	;
	rdfs:label	"define"	.

local:therapeutic_status_of_patient	a	rdf:Class	;
	rdfs:label	"therapeutic status of patient"	.

local:therapeutic_status	a	rdf:Class	;
	rdfs:label	"therapeutic status"	.

local:therapeutic	a	rdf:Class	;
	rdfs:label	"therapeutic"	.

local:status	a	rdf:Class	;
	rdfs:label	"status"	.

local:last_visit	a	rdf:Class	;
	rdfs:label	"last visit"	.

local:visit	a	rdf:Class	;
	rdfs:label	"visit"	.

local:last	a	rdf:Class	;
	rdfs:label	"last"	.

local:stable_without_immunosuppressant_stable_with_immunosuppressant	a	rdf:Class	;
	rdfs:label	"stable without immunosuppressant stable with immunosuppressant"	.

local:immunosuppressant_stable	a	rdf:Class	;
	rdfs:label	"immunosuppressant stable"	.

local:stable	a	rdf:Class	;
	rdfs:label	"stable"	.

local:stable_without_immunosuppressant_stable	a	rdf:Class	;
	rdfs:label	"stable without immunosuppressant stable"	.

local:immunosuppressant_stable_with_immunosuppressant	a	rdf:Class	;
	rdfs:label	"immunosuppressant stable with immunosuppressant"	.

local:clinical_status_of_patient	a	rdf:Class	;
	rdfs:label	"clinical status of patient"	.

local:clinical_status	a	rdf:Class	;
	rdfs:label	"clinical status"	.

local:clinical	a	rdf:Class	;
	rdfs:label	"clinical"	.

local:we	a	rdf:Class	;
	rdfs:label	"we"	.

local:clinical_course_of_patient_on_immunosuppressive_therapy	a	rdf:Class	;
	rdfs:label	"clinical course of patient on immunosuppressive therapy"	.

local:immunosuppressive_therapy	a	rdf:Class	;
	rdfs:label	"immunosuppressive therapy"	.

local:clinical_course	a	rdf:Class	;
	rdfs:label	"clinical course"	.

local:course	a	rdf:Class	;
	rdfs:label	"course"	.

local:therapy	a	rdf:Class	;
	rdfs:label	"therapy"	.

local:immunosuppressive	a	rdf:Class	;
	rdfs:label	"immunosuppressive"	.

local:clinical_course_of_patient	a	rdf:Class	;
	rdfs:label	"clinical course of patient"	.

local:patient_on_immunosuppressive_therapy	a	rdf:Class	;
	rdfs:label	"patient on immunosuppressive therapy"	.

local:evaluate_the_efficacy_of_rituximab	a	rdf:Class	;
	rdfs:label	"evaluate the efficacy of rituximab"	.

local:efficacy_of_rituximab	a	rdf:Class	;
	rdfs:label	"efficacy of rituximab"	.

local:evaluate	a	rdf:Class	;
	rdfs:label	"evaluate"	.

local:different_line_of_immunosuppressive_treatment	a	rdf:Class	;
	rdfs:label	"different line of immunosuppressive treatment"	.

local:different_line	a	rdf:Class	;
	rdfs:label	"different line"	.

local:immunosuppressive_treatment	a	rdf:Class	;
	rdfs:label	"immunosuppressive treatment"	.

local:line	a	rdf:Class	;
	rdfs:label	"line"	.

local:different	a	rdf:Class	;
	rdfs:label	"different"	.

local:collect	a	rdf:Class	;
	rdfs:label	"collect"	.

local:clinical_course_of_the_patient	a	rdf:Class	;
	rdfs:label	"clinical course of the patient"	.

local:type_of_myasthenia	a	rdf:Class	;
	rdfs:label	"type of myasthenia"	.

local:type	a	rdf:Class	;
	rdfs:label	"type"	.

local:retrospective_multicenter_study	a	rdf:Class	;
	rdfs:label	"retrospective multicenter study"	.

local:retrospective_multicenter	a	rdf:Class	;
	rdfs:label	"retrospective multicenter"	.

local:retrospective	a	rdf:Class	;
	rdfs:label	"retrospective"	.

local:multicenter_study	a	rdf:Class	;
	rdfs:label	"multicenter study"	.

local:multicenter	a	rdf:Class	;
	rdfs:label	"multicenter"	.

local:april	a	rdf:Class	;
	rdfs:label	"april"	.

local:30_2020	a	rdf:Class	;
	rdfs:label	"30 2020"	.

local:2020	a	rdf:Class	;
	rdfs:label	"2020"	.

local:conduct	a	rdf:Class	;
	rdfs:label	"conduct"	.

local:january_1_2009_to_april_30_2020	a	rdf:Class	;
	rdfs:label	"january 1 2009 to april 30 2020"	.

local:2020_january	a	rdf:Class	;
	rdfs:label	"2020 january"	.

local:january	a	rdf:Class	;
	rdfs:label	"january"	.

local:30_april	a	rdf:Class	;
	rdfs:label	"30 april"	.

local:2009_2020_january	a	rdf:Class	;
	rdfs:label	"2009 2020 january"	.

local:1_2009	a	rdf:Class	;
	rdfs:label	"1 2009"	.

local:2009	a	rdf:Class	;
	rdfs:label	"2009"	.

local:2009_2020_january_to_30_april	a	rdf:Class	;
	rdfs:label	"2009 2020 january to 30 april"	.

local:january_1_2009_to	a	rdf:Class	;
	rdfs:label	"january 1 2009 to"	.

local:2009_january	a	rdf:Class	;
	rdfs:label	"2009 january"	.

local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	a	rdf:Class	;
	rdfs:label	"new place in the therapeutic strategy of juvenile myasthenia gravis"	.

local:therapeutic_strategy	a	rdf:Class	;
	rdfs:label	"therapeutic strategy"	.

local:new_place	a	rdf:Class	;
	rdfs:label	"new place"	.

local:strategy	a	rdf:Class	;
	rdfs:label	"strategy"	.

local:new	a	rdf:Class	;
	rdfs:label	"new"	.

local:place	a	rdf:Class	;
	rdfs:label	"place"	.

local:new_place_in_therapeutic_strategy	a	rdf:Class	;
	rdfs:label	"new place in therapeutic strategy"	.

local:therapeutic_strategy_of_juvenile_myasthenia	a	rdf:Class	;
	rdfs:label	"therapeutic strategy of juvenile myasthenia"	.

local:propose	a	rdf:Class	;
	rdfs:label	"propose"	.

local:describe	a	rdf:Class	;
	rdfs:label	"describe"	.

local:french_neuromuscular_reference_network	a	rdf:Class	;
	rdfs:label	"french neuromuscular reference network"	.

local:french_neuromuscular_reference	a	rdf:Class	;
	rdfs:label	"french neuromuscular reference"	.

local:reference	a	rdf:Class	;
	rdfs:label	"reference"	.

local:neuromuscular_reference	a	rdf:Class	;
	rdfs:label	"neuromuscular reference"	.

local:neuromuscular	a	rdf:Class	;
	rdfs:label	"neuromuscular"	.

local:reference_network	a	rdf:Class	;
	rdfs:label	"reference network"	.

local:network	a	rdf:Class	;
	rdfs:label	"network"	.

local:french_neuromuscular	a	rdf:Class	;
	rdfs:label	"french neuromuscular"	.

local:neuromuscular_reference_network	a	rdf:Class	;
	rdfs:label	"neuromuscular reference network"	.

local:french	a	rdf:Class	;
	rdfs:label	"french"	.

local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	a	rdf:Class	;
	rdfs:label	"study efficacy and safety in 8 main pediatric center of the french neuromuscular reference network"	.

local:safety	a	rdf:Class	;
	rdfs:label	"safety"	.

local:study_efficacy	a	rdf:Class	;
	rdfs:label	"study efficacy"	.

local:main_pediatric_center	a	rdf:Class	;
	rdfs:label	"main pediatric center"	.

local:center	a	rdf:Class	;
	rdfs:label	"center"	.

local:pediatric_center	a	rdf:Class	;
	rdfs:label	"pediatric center"	.

local:main_pediatric	a	rdf:Class	;
	rdfs:label	"main pediatric"	.

local:pediatric	a	rdf:Class	;
	rdfs:label	"pediatric"	.

local:main	a	rdf:Class	;
	rdfs:label	"main"	.

local:8_main_pediatric_center	a	rdf:Class	;
	rdfs:label	"8 main pediatric center"	.

local:study_efficacy_in_8_main_pediatric_center	a	rdf:Class	;
	rdfs:label	"study efficacy in 8 main pediatric center"	.

local:8_main_pediatric_center_of_french_neuromuscular_reference_network	a	rdf:Class	;
	rdfs:label	"8 main pediatric center of french neuromuscular reference network"	.

local:last_international_consensus	a	rdf:Class	;
	rdfs:label	"last international consensus"	.

local:last_international	a	rdf:Class	;
	rdfs:label	"last international"	.

local:consensus	a	rdf:Class	;
	rdfs:label	"consensus"	.

local:international_consensus	a	rdf:Class	;
	rdfs:label	"international consensus"	.

local:international	a	rdf:Class	;
	rdfs:label	"international"	.

local:not_define	a	rdf:Class	;
	rdfs:label	"not define"	.

local:place_of_new_immunosuppressive_therapy	a	rdf:Class	;
	rdfs:label	"place of new immunosuppressive therapy"	.

local:new_immunosuppressive_therapy	a	rdf:Class	;
	rdfs:label	"new immunosuppressive therapy"	.

local:new_immunosuppressive	a	rdf:Class	;
	rdfs:label	"new immunosuppressive"	.

local:clearly	a	rdf:Class	;
	rdfs:label	"clearly"	.

local:hold	a	rdf:Class	;
	rdfs:label	"hold"	.

local:march_2019_due_to_the_lack_of_clinical_trial	a	rdf:Class	;
	rdfs:label	"march 2019 due to the lack of clinical trial"	.

local:lack	a	rdf:Class	;
	rdfs:label	"lack"	.

local:clinical_trial	a	rdf:Class	;
	rdfs:label	"clinical trial"	.

local:march	a	rdf:Class	;
	rdfs:label	"march"	.

local:trial	a	rdf:Class	;
	rdfs:label	"trial"	.

local:2019_due_to_lack	a	rdf:Class	;
	rdfs:label	"2019 due_to lack"	.

local:2019	a	rdf:Class	;
	rdfs:label	"2019"	.

local:lack_of_clinical_trial	a	rdf:Class	;
	rdfs:label	"lack of clinical trial"	.

#### Mapped Relations ####

local:result	owl:sameAs	ncit:C76125	.
local:visit	owl:sameAs	ncit:C25716	.
ncit:C1702	rdfs:label	"Rituximab"	.
ncit:C61300	rdfs:label	"Convention"	.
ncit:C61589	rdfs:label	"Early"	.
local:evaluate	owl:sameAs	ncit:C25214	.
ncit:C148418	rdfs:label	"Neuromuscular"	.
ncit:C64197	rdfs:label	"Consensus"	.
local:clinical_trial	owl:sameAs	ncit:C71104	.
local:discontinuation	owl:sameAs	ncit:C142444	.
ncit:C48570	rdfs:label	"Percent Unit"	.
ncit:C16326	rdfs:label	"Behavior"	.
local:percent	owl:sameAs	ncit:C48570	.
ncit:C147914	rdfs:label	"Strategy"	.
local:safety	owl:sameAs	ncit:C60828	.
ncit:C106183	rdfs:label	"April"	.
local:center	owl:sameAs	ncit:C25445	.
local:suggest	owl:sameAs	ncit:C48313	.
local:therapy	owl:sameAs	ncit:C41174	.
local:strategy	owl:sameAs	ncit:C147914	.
local:different	owl:sameAs	ncit:C46003	.
local:pediatric	owl:sameAs	ncit:C39299	.
ncit:C20200	rdfs:label	"Outcome"	.
local:have	owl:sameAs	ncit:C101282	.
ncit:C28010	rdfs:label	"Retrospective"	.
ncit:C49156	rdfs:label	"Comparison"	.
local:january	owl:sameAs	ncit:C106180	.
local:new	owl:sameAs	ncit:C25586	.
local:french	owl:sameAs	ncit:C43854	.
local:myasthenia_gravis	owl:sameAs	ncit:C60989	.
ncit:C574	rdfs:label	"Immunosuppressant"	.
ncit:C101282	rdfs:label	"Have"	.
ncit:C64975	rdfs:label	"Good"	.
local:increase	owl:sameAs	ncit:C25533	.
ncit:C106180	rdfs:label	"January"	.
ncit:C25214	rdfs:label	"Evaluation"	.
ncit:C25340	rdfs:label	"Use"	.
ncit:C179695	rdfs:label	"Specimen Appearance Assessment"	.
ncit:C25379	rdfs:label	"Course"	.
ncit:C25319	rdfs:label	"Place"	.
ncit:C25688	rdfs:label	"Status"	.
ncit:C46003	rdfs:label	"Difference"	.
ncit:C25445	rdfs:label	"Center"	.
ncit:C25398	rdfs:label	"Clinical"	.
local:use	owl:sameAs	ncit:C25340	.
local:conventional	owl:sameAs	ncit:C61300	.
local:treat	owl:sameAs	ncit:C70742	.
ncit:C25641	rdfs:label	"Reference"	.
ncit:C25716	rdfs:label	"Visit"	.
ncit:C62290	rdfs:label	"Hold"	.
ncit:C25562	rdfs:label	"Main"	.
local:france	owl:sameAs	ncit:C16592	.
local:immunosuppressant	owl:sameAs	ncit:C574	.
ncit:C15261	rdfs:label	"Immunosuppressive Therapy"	.
ncit:C16592	rdfs:label	"France"	.
local:consensus	owl:sameAs	ncit:C64197	.
ncit:C25277	rdfs:label	"Therapeutic"	.
ncit:C29848	rdfs:label	"Year"	.
local:collect	owl:sameAs	ncit:C133294	.
local:early	owl:sameAs	ncit:C61589	.
local:status	owl:sameAs	ncit:C25688	.
ncit:C41174	rdfs:label	"Therapy Object"	.
ncit:C48313	rdfs:label	"Suggestion"	.
local:therapeutic	owl:sameAs	ncit:C25277	.
local:treatment	owl:sameAs	ncit:C49236	.
local:tolerability	owl:sameAs	ncit:C98791	.
ncit:C70742	rdfs:label	"Treat"	.
ncit:C76125	rdfs:label	"Experimental Result"	.
ncit:C39299	rdfs:label	"Pediatric"	.
local:conduct	owl:sameAs	ncit:C16326	.
ncit:C98791	rdfs:label	"Tolerability Study"	.
ncit:C30103	rdfs:label	"Stable"	.
ncit:C88183	rdfs:label	"Efficacy"	.
ncit:C2291	rdfs:label	"Cortisone"	.
ncit:C25533	rdfs:label	"Increase"	.
local:immunosuppressive_therapy	owl:sameAs	ncit:C15261	.
local:clinical	owl:sameAs	ncit:C25398	.
local:clinical_course	owl:sameAs	ncit:C35461	.
ncit:C142444	rdfs:label	"Study Subject Discontinuation"	.
ncit:C71685	rdfs:label	"Better"	.
local:stable	owl:sameAs	ncit:C30103	.
ncit:C60989	rdfs:label	"Myasthenia Gravis"	.
local:place	owl:sameAs	ncit:C25319	.
local:neuromuscular	owl:sameAs	ncit:C148418	.
ncit:C71604	rdfs:label	"Line"	.
ncit:C60828	rdfs:label	"Safety"	.
local:international	owl:sameAs	ncit:C25541	.
ncit:C16104	rdfs:label	"Multi-Institutional Clinical Trial"	.
ncit:C133294	rdfs:label	"Whole Blood or Product Procurement"	.
local:multicenter_study	owl:sameAs	ncit:C16104	.
local:rituximab	owl:sameAs	ncit:C1702	.
local:good	owl:sameAs	ncit:C64975	.
local:year	owl:sameAs	ncit:C29848	.
ncit:C49236	rdfs:label	"Therapeutic Procedure"	.
ncit:C25284	rdfs:label	"Type"	.
local:line	owl:sameAs	ncit:C71604	.
local:type	owl:sameAs	ncit:C25284	.
local:main	owl:sameAs	ncit:C25562	.
local:april	owl:sameAs	ncit:C106183	.
local:appear	owl:sameAs	ncit:C179695	.
ncit:C43854	rdfs:label	"French"	.
local:better	owl:sameAs	ncit:C71685	.
local:outcome	owl:sameAs	ncit:C20200	.
local:course	owl:sameAs	ncit:C25379	.
local:reference	owl:sameAs	ncit:C25641	.
local:march	owl:sameAs	ncit:C106182	.
local:compare	owl:sameAs	ncit:C49156	.
ncit:C25586	rdfs:label	"New"	.
local:retrospective	owl:sameAs	ncit:C28010	.
local:efficacy	owl:sameAs	ncit:C88183	.
local:network	owl:sameAs	ncit:C61377	.
ncit:C35461	rdfs:label	"Clinical Course of Disease"	.
local:cortisone	owl:sameAs	ncit:C2291	.
ncit:C25541	rdfs:label	"International"	.
ncit:C71104	rdfs:label	"Clinical Trial"	.
ncit:C106182	rdfs:label	"March"	.
ncit:C61377	rdfs:label	"Network"	.
local:hold	owl:sameAs	ncit:C62290	.

#### Relations ####

local:2009_2020_january	rdfs:subClassOf	local:2020_january	.
local:conventional_immunosuppressant	rdfs:subClassOf	local:immunosuppressant	.
local:s3.1	rdf:subject	local:french_neuromuscular_reference_network	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:immunosuppressant	.
local:cortisone_spar	rdfs:member	local:cortisone	.
local:early_use	rdfs:member	local:early	.
local:main_pediatric_center	rdfs:member	local:main_pediatric	.
local:lack_of_clinical_trial	rdfs:member	local:lack	.
local:s1	rdf:subject	local:last_international_consensus	.
local:s22	rdf:subject	local:use_of_rituximab_a_a_firstline_immunosuppressant	.
local:patient_in_cortisone_spar	rdfs:member	local:patient	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:rituximab_treatment	.
local:s4	rdf:predicate	local:describe	.
local:clinical_trial	rdfs:subClassOf	local:trial	.
local:patient_on_immunosuppressive_therapy	rdfs:member	local:immunosuppressive_therapy	.
local:s25	rdf:subject	local:use_of_rituximab_a_a_firstline_immunosuppressant	.
local:clinical_course_of_the_patient	rdfs:member	local:patient	.
local:s10	rdf:subject	local:clinical_course_of_the_patient	.
local:s21	rdf:object	local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	.
local:new_immunosuppressive_therapy	rdfs:subClassOf	local:immunosuppressive_therapy	.
local:neuromuscular_reference_network	rdfs:subClassOf	local:reference_network	.
local:s9	rdf:predicate	local:collect	.
local:s14	rdf:object	local:clinical_status_of_patient	.
local:new_immunosuppressive	rdfs:member	local:new	.
local:compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:rituximab_treatment	.
local:s12.1	rdf:subject	local:we	.
local:s14	rdf:subject	local:outcome	.
local:cortisone_spar_compare	rdfs:subClassOf	local:compare	.
local:french_neuromuscular_reference_network	rdfs:subClassOf	local:network	.
local:study_efficacy	rdfs:member	local:study	.
local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	rdfs:member	local:good_tolerability	.
local:s1	rdf:predicate	local:hold	.
local:s14	rdf:predicate	local:define	.
local:s24	rdf:subject	local:rituximab	.
local:patient_on_immunosuppressive_therapy	rdfs:member	local:patient	.
local:lack_of_clinical_trial	rdfs:member	local:clinical_trial	.
local:new_place_in_therapeutic_strategy	rdfs:member	local:new_place	.
local:better_outcome	rdfs:member	local:better	.
local:clinical_status_of_patient	rdfs:member	local:clinical_status	.
local:better_efficacy_with_discontinuation	rdfs:member	local:discontinuation	.
local:s4.1	rdf:subject	local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	.
local:s21.1	rdf:predicate	local:spar	.
local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	rdfs:member	local:safety	.
local:good_tolerability_of_rituximab_in_juvenile_myasthenia	rdfs:member	local:juvenile_myasthenia	.
local:s27.2	rdf:predicate	local:spar	.
local:s29.1	rdf:object	local:outcome	.
local:s2	local:AM-MNR	local:clearly	.
local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	rdfs:member	local:study_efficacy	.
local:immunosuppressant_stable	rdfs:subClassOf	local:stable	.
local:type_of_myasthenia	rdfs:member	local:type	.
local:compare_with_rituximab_treatment	rdfs:member	local:compare	.
local:immunosuppressant_stable_with_immunosuppressant	rdfs:member	local:immunosuppressant_stable	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:patient	.
local:s5	rdf:predicate	local:conduct	.
local:good_tolerability_of_rituximab	rdfs:member	local:good_tolerability	.
local:8_main_pediatric_center	rdfs:subClassOf	local:main_pediatric_center	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:cortisone_spar_compare	.
local:s18	rdf:object	local:better_outcome_than_patient	.
local:retrospective_multicenter_study	rdfs:subClassOf	local:multicenter_study	.
local:march_2019_due_to_the_lack_of_clinical_trial	rdfs:member	local:march	.
local:juvenile_myasthenia	rdfs:member	local:juvenile	.
local:better_outcome_than_patient	rdfs:member	local:patient	.
local:neuromuscular_reference	rdfs:subClassOf	local:reference	.
local:cortisone_spar_compare	rdfs:member	local:cortisone_spar	.
local:s27.1	rdf:predicate	local:facilitate	.
local:compare_with_rituximab_treatment	rdfs:member	local:rituximab_treatment	.
local:s20	rdf:predicate	local:show	.
local:immunosuppressive_therapy	rdfs:subClassOf	local:therapy	.
local:clinical_course	rdfs:subClassOf	local:course	.
local:s2	rdf:object	local:place_of_new_immunosuppressive_therapy	.
local:efficacy_of_rituximab	rdfs:member	local:efficacy	.
local:s21.1	rdf:object	local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	.
local:s4.1	rdf:predicate	local:propose	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:discontinuation	.
local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:compare	.
local:s26	rdf:object	local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	.
local:clinical_course	rdfs:member	local:clinical	.
local:early_use	rdfs:subClassOf	local:use	.
local:therapeutic_status_of_patient	rdfs:member	local:therapeutic_status	.
local:main_pediatric	rdfs:member	local:main	.
local:2009_2020_january_to_30_april	rdfs:member	local:2009_2020_january	.
local:thirdline_immunosuppression	rdfs:member	local:thirdline	.
local:last_10_year	rdfs:subClassOf	local:10_year	.
local:s16	local:AM-TMP	local:last_visit	.
local:rituximab_treatment	rdfs:member	local:rituximab	.
local:therapeutic_strategy	rdfs:member	local:therapeutic	.
local:s8	rdf:predicate	local:conduct	.
local:spar_compare	rdfs:member	local:spar	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:better_efficacy	.
local:s27.1	rdf:subject	local:early_use	.
local:cortisone_spar_in_antibodypositive	rdfs:member	local:antibodypositive	.
local:good_tolerability_of_rituximab_in_juvenile_myasthenia	rdfs:member	local:good_tolerability_of_rituximab	.
local:clinical_course_of_patient_on_immunosuppressive_therapy	rdfs:member	local:patient	.
local:2019_due_to_lack	rdfs:member	local:lack	.
local:s15	rdf:subject	local:outcome	.
local:s17	rdf:predicate	local:treat	.
local:study_efficacy	rdfs:subClassOf	local:efficacy	.
local:s3	rdf:predicate	local:describe	.
local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	rdfs:member	local:juvenile_myasthenia_gravis	.
local:good_tolerability_of_rituximab	rdfs:member	local:rituximab	.
local:better_efficacy	rdfs:member	local:better	.
local:last_international_consensus	rdfs:subClassOf	local:international_consensus	.
local:s20	rdf:object	local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	.
local:s15	local:AM-MNR	local:stable_without_immunosuppressant_stable_with_immunosuppressant	.
local:s2	rdf:predicate	local:not_define	.
local:last_10_year_a_a_firstline_immunosuppressant	rdfs:member	local:year	.
local:new_place_in_therapeutic_strategy	rdfs:member	local:therapeutic_strategy	.
local:s23	rdf:predicate	local:show	.
local:therapeutic_strategy_of_juvenile_myasthenia	rdfs:member	local:juvenile_myasthenia	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:better_efficacy	.
local:s8	rdf:subject	local:we	.
local:retrospective_multicenter_study	rdfs:member	local:retrospective_multicenter	.
local:study_efficacy_in_8_main_pediatric_center	rdfs:member	local:8_main_pediatric_center	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:better_efficacy	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:rituximab_treatment	.
local:conventional_immunosuppressant	rdfs:member	local:conventional	.
local:s12.1	rdf:object	local:clinical_course_of_patient_on_immunosuppressive_therapy	.
local:s24	rdf:predicate	local:tolerate	.
local:clinical_course_of_patient_on_immunosuppressive_therapy	rdfs:member	local:immunosuppressive_therapy	.
local:different_line_of_immunosuppressive_treatment	rdfs:member	local:different_line	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:result	.
local:s12	rdf:subject	local:we	.
local:neuromuscular_reference	rdfs:member	local:neuromuscular	.
local:discontinuation_of_immunosuppressant	rdfs:member	local:immunosuppressant	.
local:s20.1	rdf:predicate	local:spar	.
local:better_outcome	rdfs:subClassOf	local:outcome	.
local:s21	rdf:subject	local:use_of_rituximab_a_a_firstline_immunosuppressant	.
local:french_neuromuscular	rdfs:member	local:french	.
local:pediatric_center	rdfs:subClassOf	local:center	.
local:s23.1	rdf:predicate	local:spar	.
local:main_pediatric_center	rdfs:subClassOf	local:center	.
local:s8	rdf:object	local:retrospective_multicenter_study	.
local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	rdfs:member	local:new_place	.
local:french_neuromuscular_reference	rdfs:subClassOf	local:reference	.
local:retrospective_multicenter	rdfs:member	local:retrospective	.
local:s21.1	rdf:subject	local:cortisone	.
local:therapeutic_status	rdfs:subClassOf	local:status	.
local:myasthenia_gravis	rdfs:subClassOf	local:gravis	.
local:s22.1	local:AM-ADV	local:compare_with_rituximab_treatment_a_a_secondline	.
local:juvenile_myasthenia_gravis	rdfs:subClassOf	local:gravis	.
local:place_of_new_immunosuppressive_therapy	rdfs:member	local:place	.
local:french_neuromuscular	rdfs:subClassOf	local:neuromuscular	.
local:cortisone_spar	rdfs:subClassOf	local:spar	.
local:s17	rdf:subject	local:patient	.
local:french_neuromuscular_reference_network	rdfs:member	local:french_neuromuscular_reference	.
local:reference_network	rdfs:subClassOf	local:network	.
local:75_percent	rdfs:subClassOf	local:percent	.
local:multicenter_study	rdfs:member	local:multicenter	.
local:s17	rdf:object	local:conventional_immunosuppressant	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:cortisone_spar_compare	.
local:stable_without_immunosuppressant_stable	rdfs:member	local:stable	.
local:s24	local:AM-MNR	local:well	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:discontinuation	.
local:juvenile_myasthenia_gravis	rdfs:member	local:juvenile_myasthenia	.
local:s29.1	rdf:subject	local:early_use	.
local:s21	rdf:predicate	local:show	.
local:s29.1	rdf:predicate	local:improve	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:rituximab_treatment	.
local:new_immunosuppressive_therapy	rdfs:member	local:new_immunosuppressive	.
local:s29	rdf:predicate	local:appear	.
local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:rituximab_treatment	.
local:french_neuromuscular_reference_network	rdfs:subClassOf	local:neuromuscular_reference_network	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:patient	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:cortisone_spar_compare	.
local:s20.1	local:AM-ADV	local:compare_with_rituximab_treatment_a_a_secondline	.
local:clinical_course_of_the_patient	rdfs:member	local:clinical_course	.
local:use_of_rituximab_a_a_firstline_immunosuppressant	rdfs:member	local:firstline_immunosuppressant	.
local:last_international_consensus	rdfs:subClassOf	local:consensus	.
local:clinical_status	rdfs:member	local:clinical	.
local:last_international_consensus	rdfs:member	local:last_international	.
local:2019_due_to_lack	rdfs:member	local:2019	.
local:neuromuscular_reference_network	rdfs:subClassOf	local:network	.
local:cortisone_spar_in_antibodypositive	rdfs:member	local:cortisone_spar	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:discontinuation	.
local:retrospective_multicenter	rdfs:subClassOf	local:multicenter	.
local:s11	rdf:predicate	local:collect	.
local:last_international	rdfs:member	local:last	.
local:better_efficacy	rdfs:subClassOf	local:efficacy	.
local:s22	rdf:predicate	local:show	.
local:immunosuppressant_stable_with_immunosuppressant	rdfs:member	local:immunosuppressant	.
local:use_of_rituximab_a_a_firstline_immunosuppressant	rdfs:member	local:use	.
local:s27.1	rdf:object	local:cortisone_spar_in_antibodypositive	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:cortisone_spar_compare	.
local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	rdfs:member	local:rituximab	.
local:s4	rdf:subject	local:use_of_rituximab	.
local:2009_january	rdfs:subClassOf	local:january	.
local:s19	rdf:predicate	local:treat	.
local:s8.1	rdf:object	local:30_2020	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:discontinuation	.
local:discontinuation_of_immunosuppressant_in_75_percent	rdfs:member	local:75_percent	.
local:s8.1	rdf:predicate	local:april	.
local:spar_compare	rdfs:subClassOf	local:compare	.
local:pediatric_center	rdfs:member	local:pediatric	.
local:8_main_pediatric_center_of_french_neuromuscular_reference_network	rdfs:member	local:french_neuromuscular_reference_network	.
local:better_outcome_than_patient	rdfs:member	local:better_outcome	.
local:clinical_status	rdfs:subClassOf	local:status	.
local:different_line_of_immunosuppressive_treatment	rdfs:member	local:immunosuppressive_treatment	.
local:new_immunosuppressive_therapy	rdfs:subClassOf	local:therapy	.
local:better_efficacy_with_discontinuation	rdfs:member	local:better_efficacy	.
local:myasthenia_gravis	rdfs:member	local:myasthenia	.
local:discontinuation_of_immunosuppressant	rdfs:member	local:discontinuation	.
local:s25	rdf:predicate	local:increase	.
local:s26	rdf:subject	local:study	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:percent	.
local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	rdfs:member	local:therapeutic_strategy	.
local:s12	rdf:object	local:efficacy_of_rituximab	.
local:8_main_pediatric_center_of_french_neuromuscular_reference_network	rdfs:member	local:8_main_pediatric_center	.
local:s25	local:AM-TMP	local:last_10_year_a_a_firstline_immunosuppressant	.
local:multicenter_study	rdfs:subClassOf	local:study	.
local:s16	rdf:subject	local:outcome	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:result	.
local:s5	rdf:object	local:retrospective_multicenter_study	.
local:s1	local:AM-TMP	local:march_2019_due_to_the_lack_of_clinical_trial	.
local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	rdfs:member	local:french_neuromuscular_reference_network	.
local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	rdfs:member	local:efficacy	.
local:stable_without_immunosuppressant_stable	rdfs:member	local:immunosuppressant_stable	.
local:result_in_cortisone_spar	rdfs:member	local:cortisone_spar	.
local:s20.1	rdf:subject	local:cortisone	.
local:main_pediatric_center	rdfs:subClassOf	local:pediatric_center	.
local:evaluate_the_efficacy_of_rituximab	rdfs:member	local:rituximab	.
local:s27	rdf:subject	local:early_use	.
local:2020_january	rdfs:subClassOf	local:january	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:secondline	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:percent	.
local:s20	rdf:subject	local:use_of_rituximab_a_a_firstline_immunosuppressant	.
local:s19	rdf:subject	local:patient	.
local:s10	rdf:predicate	local:collect	.
local:s26	rdf:predicate	local:suggest	.
local:s29	rdf:subject	local:early_use	.
local:international_consensus	rdfs:member	local:international	.
local:evaluate_the_efficacy_of_rituximab	rdfs:member	local:efficacy	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:immunosuppressant	.
local:clinical_course_of_patient	rdfs:member	local:clinical_course	.
local:s5	local:AM-TMP	local:january_1_2009_to	.
local:10_year	rdfs:subClassOf	local:year	.
local:use_of_rituximab	rdfs:member	local:use	.
local:75_percent_of_patient	rdfs:member	local:patient	.
local:s11	rdf:subject	local:different_line_of_immunosuppressive_treatment	.
local:s4	local:AM-PNC	local:s4.1	.
local:study_efficacy_in_8_main_pediatric_center	rdfs:member	local:study_efficacy	.
local:s23	rdf:object	local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	.
local:clinical_trial	rdfs:member	local:clinical	.
local:s27.2	local:AM-LOC	local:antibodypositive	.
local:use_of_rituximab_a_a_firstline_immunosuppressant	rdfs:member	local:rituximab	.
local:s18	rdf:predicate	local:have	.
local:30_2020	rdfs:subClassOf	local:2020	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:rituximab_treatment	.
local:place_of_new_immunosuppressive_therapy	rdfs:member	local:new_immunosuppressive_therapy	.
local:good_tolerability	rdfs:member	local:good	.
local:good_tolerability	rdfs:subClassOf	local:tolerability	.
local:good_tolerability_and_efficacy_of_rituximab_in_juvenile_myasthenia_gravis	rdfs:member	local:juvenile_myasthenia_gravis	.
local:therapeutic_strategy	rdfs:subClassOf	local:strategy	.
local:use_of_rituximab	rdfs:member	local:rituximab	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:percent	.
local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	rdfs:member	local:main_pediatric_center	.
local:s23.1	rdf:object	local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	.
local:march_2019_due_to_the_lack_of_clinical_trial	rdfs:member	local:clinical_trial	.
local:immunosuppressive_therapy	rdfs:member	local:immunosuppressive	.
local:s12	rdf:predicate	local:evaluate	.
local:s9	rdf:subject	local:type_of_myasthenia	.
local:last_10_year_a_a_firstline_immunosuppressant	rdfs:member	local:firstline_immunosuppressant	.
local:efficacy_of_rituximab	rdfs:member	local:rituximab	.
local:patient_in_cortisone_spar	rdfs:member	local:cortisone_spar	.
local:30_april	rdfs:subClassOf	local:april	.
local:new_place	rdfs:subClassOf	local:place	.
local:international_consensus	rdfs:subClassOf	local:consensus	.
local:s8	local:AM-TMP	local:january_1_2009_to_april_30_2020	.
local:firstline_immunosuppressant	rdfs:member	local:firstline	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:better_efficacy	.
local:s3.1	rdf:object	local:new_place_in_the_therapeutic_strategy_of_juvenile_myasthenia_gravis	.
local:clinical_status_of_patient	rdfs:member	local:patient	.
local:s25	local:AM-LOC	local:france	.
local:s22.1	rdf:subject	local:cortisone	.
local:s12.1	local:AM-PNC	local:evaluate_the_efficacy_of_rituximab	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:secondline	.
local:compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:thirdline_immunosuppression	.
local:therapeutic_status_of_patient	rdfs:member	local:patient	.
local:new_place	rdfs:member	local:new	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:immunosuppressant	.
local:neuromuscular_reference_network	rdfs:member	local:neuromuscular_reference	.
local:s15	rdf:predicate	local:define	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:thirdline_immunosuppression	.
local:s3	local:AM-PNC	local:s4.1	.
local:s22	rdf:object	local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	.
local:reference_network	rdfs:member	local:reference	.
local:s3	rdf:subject	local:study_efficacy_and_safety_in_8_main_pediatric_center_of_the_french_neuromuscular_reference_network	.
local:main_pediatric	rdfs:subClassOf	local:pediatric	.
local:rituximab_treatment	rdfs:subClassOf	local:treatment	.
local:compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:compare	.
local:clinical_course_of_patient	rdfs:member	local:patient	.
local:discontinuation_of_immunosuppressant_in_75_percent	rdfs:member	local:discontinuation_of_immunosuppressant	.
local:s27	rdf:predicate	local:appear	.
local:s19	rdf:object	local:rituximab	.
local:75_percent_of_result	rdfs:member	local:result	.
local:s16	rdf:predicate	local:define	.
local:last_visit	rdfs:member	local:last	.
local:s2	rdf:subject	local:last_international_consensus	.
local:type_of_myasthenia	rdfs:member	local:myasthenia	.
local:s5	rdf:subject	local:we	.
local:1_2009	rdfs:subClassOf	local:2009	.
local:french_neuromuscular_reference	rdfs:member	local:french_neuromuscular	.
local:different_line	rdfs:subClassOf	local:line	.
local:immunosuppressive_treatment	rdfs:member	local:immunosuppressive	.
local:therapeutic_status	rdfs:member	local:therapeutic	.
local:s3.1	rdf:predicate	local:propose	.
local:s12.1	rdf:predicate	local:study	.
local:therapeutic_strategy_of_juvenile_myasthenia	rdfs:member	local:therapeutic_strategy	.
local:s18	rdf:subject	local:patient	.
local:75_percent_of_result	rdfs:member	local:75_percent	.
local:juvenile_myasthenia	rdfs:subClassOf	local:myasthenia	.
local:s23.1	rdf:subject	local:cortisone	.
local:s8.1	rdf:subject	local:retrospective_multicenter_study	.
local:75_percent_of_patient	rdfs:member	local:75_percent	.
local:s16	rdf:object	local:therapeutic_status_of_patient	.
local:s14	local:AM-TMP	local:last_visit	.
local:compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:secondline	.
local:s22.1	rdf:predicate	local:spar	.
local:2009_2020_january_to_30_april	rdfs:member	local:30_april	.
local:last_international	rdfs:subClassOf	local:international	.
local:thirdline_immunosuppression	rdfs:subClassOf	local:immunosuppression	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_patient_in_cortisone_spar_compare_with_rituximab_treatment_a_a_secondline	rdfs:member	local:percent	.
local:new_immunosuppressive	rdfs:subClassOf	local:immunosuppressive	.
local:result_in_cortisone_spar	rdfs:member	local:result	.
local:clinical_course_of_patient_on_immunosuppressive_therapy	rdfs:member	local:clinical_course	.
local:last_visit	rdfs:subClassOf	local:visit	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:thirdline_immunosuppression	.
local:march_2019_due_to_the_lack_of_clinical_trial	rdfs:member	local:lack	.
local:immunosuppressive_treatment	rdfs:subClassOf	local:treatment	.
local:s27.2	rdf:subject	local:cortisone	.
local:s23	rdf:subject	local:use_of_rituximab_a_a_firstline_immunosuppressant	.
local:retrospective_multicenter_study	rdfs:subClassOf	local:study	.
local:firstline_immunosuppressant	rdfs:subClassOf	local:immunosuppressant	.
local:different_line	rdfs:member	local:different	.
local:better_efficacy_with_a_discontinuation_of_immunosuppressant_in_75_percent_of_result_in_cortisone_spar_compare_with_rituximab_treatment_a_thirdline_immunosuppression	rdfs:member	local:immunosuppressant	.
